Background This study aims to compare the effectiveness and safety of nirmatrelvir/ritonavir
(Paxlovid) and sotrovimab for coronavirus disease 2019 (COVID-19). Methods A search was …

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Objectives A reappraisal of the validity of the conclusions of systematic reviews (SRs)
related to nirmatrelvir/ritonavir for the treatment of COVID-19. Methods An overview of SRs …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …

Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus
disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome …

Objective To assess the effectiveness of nirmatrelvir-ritonavir in the treatment of outpatients
with mild to moderate COVID-19 who are at higher risk of developing severe illness, through …